In vivo and in vitro experiments suggested that IL-37 binds to TLR receptor-2 or TLR receptor-4 on the cell surface, inhibits the activation of NF-κB, inhibits the production of monocyte chemotactic protein 1 (MCP1) and monocyte aggregation, promotes the secretion of TGF-β, alleviates inflammatory reaction, and improves myocardial ischemia and left ventricular function [15]. Here, TGFB1 is linked to myocardial ischemia.